Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Bozzuto

Undersea and Hyperbaric Medicine Scranton, PA Doctor of Osteopathy

NPI 1164494720 CMS profile 97614

300 Lackawanna Ave Ste 150, Scranton, PA 18503

Open in the dashboard

General payments

$6,105

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Bozzuto of Scranton, PA is reported in the CMS Open Payments database as having received $6,105 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $243 11
2024 General $275 13
2023 General $207 6
2022 General $195 5
2021 General $319 10
2020 General $159 10
2019 General $4,707 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Bozzuto
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Thomas Bozzuto were reported at $243. Among 65 Undersea and Hyperbaric Medicine profiles paid that year, the median was $153 and the middle half received between $68 and $340.

Show as a table
Year Thomas Bozzuto Undersea and Hyperbaric Medicine median Middle half National median
2019 $4,707 $162 $85–$376 $163
2020 $159 $111 $46–$307 $114
2021 $319 $154 $50–$306 $132
2022 $195 $122 $40–$378 $149
2023 $207 $145 $52–$410 $160
2024 $275 $146 $80–$316 $164
2025 $243 $153 $68–$340 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. KCI USA, Inc $4,280 3 payments
  2. Smith+Nephew, Inc. $1,269 57 payments
  3. Novo Nordisk Inc $126 1 payment
  4. Hollister Incorporated $81 1 payment
  5. Aroa Biosurgery Incorporated $64 3 payments
  6. Integra LifeSciences Corporation $53 3 payments
  7. Organogenesis Inc. $38 2 payments
  8. Allergan Inc. $30 1 payment
  9. Sechrist Industries Inc $29 1 payment
  10. Melinta Therapeutics, Inc. $29 2 payments
  11. Other $105 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,200 1 payment
  2. Food and Beverage $1,905 79 payments
Products named General payments · program years 2019–2025
  1. KERRAFOAM GENTLE BORDER $4,200 1 payment
  2. COLLAGENASE SANTYL Pharma Products $421 24 payments
  3. Santyl $274 14 payments
  4. REGRANEX $241 11 payments
  5. COLLAGENASE SANTYL Pharma Product $145 6 payments
  6. RYBELSUS $126 1 payment
  7. RENASYS Touch $110 3 payments
  8. GRAFIX PL $109 1 payment
  9. Oasis $103 1 payment
  10. New Image $81 1 payment
  11. Other $970 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

139

Prescriptions dispensed, refills included

Drug cost

$41,084

Paid at the pharmacy, in all

Branded share of claims

26.6%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 37 $36,849
Pentoxifylline Generic 69 $4,006
Triamcinolone Acetonide Generic 33 $230

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$143,459

Of which drugs: $3,952

Medicare patients

235

Average age 73

Services billed

1,736

111 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 51%
Ischemic heart disease 42%
Chronic kidney disease 41%
Heart failure 38%
Atrial fibrillation 34%
Depression 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record